
PRESS RELEASE

STOCKHOLM, OCTOBER 13, 2023

Prominent U.S. hospital expands RayStation installation for proton treatment planning

RaySearch Laboratories AB (publ) announces that the Mass General Cancer Center plans to expand its use of RayStation® to proton treatment planning.*

RayStation is a flexible, innovative cancer treatment planning system developed by RaySearch. The software offers features for proton therapy planning such as multi-criteria optimization, LET evaluation, and optimization, as well as modalities under development such as proton arcs and FLASH.

The Mass General Cancer Center, which was the first in the world to offer proton therapy, is in the process of transitioning its proton treatment planning system to RayStation. The center has been using RayStation for photon radiation therapy planning for more than 10 years. By expanding its clinical use to include protons, all external beam planning will now be done on a single platform.

David Gierga, PhD, Director of Clinical Physics Operations in Radiation Oncology at the Mass General Cancer Center, says: "We are excited to streamline our treatment planning operations and look forward to having access to new and exciting developments in proton planning."

Harald Paganetti, PhD, Director of Physics Research in Radiation Oncology at the Mass General Cancer Center, says: "We have had access to RayStation for many years, and my team and I are pleased that the system soon will be used clinically for proton planning as well as. This will expedite the translation of research findings and new technologies into the clinic."

Johan Löf, founder and CEO, RaySearch, says: "Mass General is truly a pioneering collaboration partner to RaySearch. They were one of the very first users of RayStation in the world and we have benefitted greatly from various collaboration projects that we have done together during the years. I am happy that they now have the opportunity to start using RayStation also for their proton treatments."

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system which enables cancer

clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.

RaySearch's software has been sold to over 900 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

About RayStation

RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.

** Subject to regulatory clearance in some markets.*

For more information, please contact:

Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)

Telephone: +46 (0) 8 510 530 00

johan.lof@raysearchlabs.com